Kornimate/medical-research-clean huggingface dataset:
effects of planned training and music listened to before a cesarean section on surgical fear, anxiety and depression

Conditions: Cesarean Section

Summary: this research was conducted to determine the effect of training and listening to music before a cesarean section on the surgical fear, anxiety and depression

the sample of the experimental study consisted of 120 pregnant women (music: 40, training: 40, control: 40). the data were collected using the personal information form, surgical fear questionnaire, and the hospital anxiety and depression scale. after the training and listening to music applications, statistically significant differences were found between the music, training, and the control groups in terms of the short-term, long-term sub-scale scores and the overall score of the surgical fear questionnaire, and the anxiety sub-scale scores of the hospital anxiety and depression scale (p \< .05). listening to music before the cesarean section was effective in reducing women's short-term and general surgical fears, and the training was also effective in reducing their short-term, long-term, and general surgical fears and anxiety levels.

Eligibility criteria:
inclusion criteria: * women who were hospitalized for planned cesarean section, * having the first pregnancy, * between the ages 19 and 35, * who had no diagnosis of a physical or mental disease, * who had no physical illness in her baby exclusion criteria: -

Keywords: anxiety and depression fear of surgery listening to music planned training cesarean section
nocturnal symptoms and quality of life in patients with parkinson's disease in shanghai

Conditions: Parkinson's Disease

Summary: this is a cross-sectional, retrospective clinical observation study focusing on the incidence and influencing factors of nocturnal symptoms in patients with parkinson's disease.

this study was a cross-sectional, retrospective clinical observation study investigating the incidence and influencing factors of nocturnal symptoms in patients with parkinson's disease through the parkinson's disease sleep-related scale. at the same time, the effects of nocturnal symptoms on the quality of life of patients with parkinson's disease were studied. about 1,500 parkinson's patients will be recruited into the study who come from shanghai, china.

Eligibility criteria:
inclusion criteria: 1. parkinson's disease patients diagnosed according to the diagnostic criteria of mds 2. signing informed consent exclusion criteria: 1. clinically suspected parkinson's disease, has not been diagnosed; 2. suspected or diagnosed as secondary parkinson's syndrome (vascular, drug, traumatic, encephalitis, toxic, etc.); 3. suspected or diagnosed as atypical parkinson's syndrome (progressive supranuclear palsy, multiple system atrophy, cortical basal ganglia degeneration, etc.); 4. there is a clear history of stroke, moderate to severe traumatic brain injury, hydrocephalus, brain surgery or history of brain tumors; 5. severe cognitive impairment or psychiatric symptoms; 6. can not cooperate with the completion of the study.
persistence, adherence and clinical effectiveness of entecavir in chronic hepatitis b patients

Conditions: Hepatitis B, Chronic

Summary: the purpose of this observational study is to measure the real-life persistence, adherence and clinical effectiveness of entecavir in patients with chronic hepatitis b viral infection.

sampling method: probability sample (consecutive patient sampling)

Eligibility criteria:
inclusion criteria: * male and female treatment naïve or pre-treated chb patients of at least 18 years of age * written informed consent exclusion criteria: * all relevant conditions according to summary of product characteristics (smpc) * human immunodeficiency virus (hiv), hepatitis c virus (hcv) or hepatitis d virus (hdv) co-infection * patients currently included in any investigational trial on chb
open-label extension study of seralutinib in adult subjects with pah (prosera-ext)

Conditions: Pulmonary Arterial Hypertension

Summary: this open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

the treatment period is planned to run until the market approval of seralutinib or until the study is terminated.

Eligibility criteria:
inclusion criteria: 1. subjects must have completed a qualifying last visit in a prior seralutinib pah study on investigational product (ip) and in accordance with the protocol. 2. evidence of an informed consent document, signed and dated by the subject, indicating that the subject has been informed of all pertinent aspects of the study prior to initiation of any subject-mandated procedures. 3. willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures 4. women of childbearing potential (wocbp) must have a negative urine or serum pregnancy test at enrollment visit before first administration of investigational product (ip) in this study. 5. wocbp who are not abstinent and intend to be sexually active with a non-sterilized male partner must be willing to use a highly effective method of contraception from consent through 30 days following the last administration of ip. 6. male subjects: non-sterilized male subjects who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom from consent through 90 days after the last dose of ip. exclusion criteria: 1. severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or seralutinib administration, unless associated with an ongoing ae and discussed with the sponsor's medical monitor (mm) (or designee). 2. have any other condition or reason that, in the opinion of the investigator, would prohibit the subject from participating in the study.

Keywords: seralutinib gb002 prosera prosera-ext
the predictive factors of vision recovery in patients with pituitary tumor

Conditions: Pituitary Adenomas

Summary: pituitary adenomas can cause compression of optic nerves and chiasm, which will lead to damage of vision. this study aims to evaluate the predictive factors for recovery of vision in patients with pituitary adenomas following trans-sphenoidal surgery.


Eligibility criteria:
inclusion criteria: * \>18 years old * patients with pituitary adenomas, loss of visual field * patients receive trans-sphenoidal surgery exclusion criteria: * visual damage caused by other diseases

Keywords: pituitary adenomas recovery of vision trans-sphenoidal surgery
niclosamide with etanercept in rheumatoid arthritis

Conditions: Rheumatoid Arthritis (RA)

Summary: assessment of the adjuvant use niclosamide with etanercept in rheumatoid arthritis

in this randomized double blind placebo-controlled pilot study (phase i study) we will assess the efficacy and safety of adjuvant use niclosamide with etanercept in rheumatoid arthritis.

Eligibility criteria:
inclusion criteria: * patients with ra, as defined by the american college of rheumatology (acr) 1987 revised criteria or acr/eular 2010, * severly active ra by calculating either das28 or sdai or cdai. * patient selected are those who started etanercept for less than 3months and still active. exclusion criteria: * patients on nonsteroidal anti-inflammatory drugs (nsaid) 2 days before entry into this study. or methotrexate (mtx).. * patients with hypersensitivity or severe adverse effects to niclosamide . * renal impairment. * hepatic impairment. * pregnancy or a desire to become pregnant. * breast feeding. * patients with juvenile ra \[16 years old or younger\]. * patients using other conventional disease modifying antirheumatic drugs (dmards). * patients on steroid. * patients with coexistence other connective tissue diseases or hypothyroid disease. * patient with mild or inactive ra.

Keywords: niclosamide rheumatoid arthritis diseases activity efficacy safety
a comparison of silicone versus polyvinylchloride (pvc) drains following vats lobectomy

Conditions: Postoperative Pain; Postoperative Complications

Summary: the goal of this prospective randomized clinical trial is to compare the impact of the chest tube type on pain, chest drainage efficacy and early postoperative outcome following vats lobectomy for lung cancer. the main questions it aims to answer are: * silicone chest drains are less painful compared to standard pvc drains? * is there any difference in chest drainage efficacy and short term outcome between the two groups? researchers will compare silicone chest drain group with pvc chest drain group to see if there is any difference in postoperative pain, chest drainage efficacy and short term outcome.


Eligibility criteria:
inclusion criteria: * primary lung cancer eligible for vats lobectomy by tumor board meeting exclusion criteria: * age under 18 years * high risk of post-operative complications (asa \> 3, diffusion capacity for transfer factor (tlco) or forced expiratory volume at one second (fev1) ≤ 40%, cycle ergometry with oxygen consumption (vo2 max) \< 15 ml/kg/min) * tumors growing in parietal pleura * extended lung resection diffuse * previous surgery in the same hemithorax * chronic pain * chronic use of analgesics or sedatives * surgical revision * inability to participate in the study.

Keywords: vats lung lobectomy postoperative pain chest drain analgesia
study of cellular impairments involved in diabetic complications

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to examine if an early detectable dysfunction in a cellular component (mitochondria) may predict complications in diabetes mellitus.


Eligibility criteria:
inclusion criteria: * diabetes mellitus exclusion criteria: * age below 18 yrs * psychiatric disease * other metabolic disease
analysis of neutrophil extracellular traps in hypercoagulability and portal vein thrombosis in liver cirrhosis patients

Conditions: Neutrophil Extracellular Trap Formation; Portal Vein Thrombosis; Liver Cirrhosis

Summary: the aim of this study was to investigate whether nets markers can enhance procoagulant activity and predict portal vein thrombosis in patients with live cirrhosis, so as to establish a novel predictor to guide clinical decision-making.so we recruit liver cirrhosis with portal vein thrombosis and without portal vein thrombosis treated at the affiliated hospital of qingdao university and collection of blood samples.

seventy-nine patients with benign liver cirrhosis treated at the affiliated hospital of qingdao university (china) from september 2020 to january 2021 were recruited for this study, including 26 patients with portal vein thrombosis and 53 patients without portal vein thrombosis. nets markers (myeloperoxidase, neutrophil elastase, citrate histone h3), tissue factor, endotoxin, factor x, tat complex, and anti-β2 glycoprotein i were detected in plasma using capture elisa and specific elisa kits. t-test was performed to analyze whether there was a statistical difference between the two groups, and regression analysis was performed between nets markers and tissue factor, endotoxin, factor x, tat complex, and anti-β2 glycoprotein i to investigate whether there was a correlation. this study without any intervention measures, will not cause harm.

Eligibility criteria:
inclusion criteria: （1) clinical diagnosis of liver cirrhosis (2) clinical diagnosis of portal vein thrombosis exclusion criteria: 1. primary or secondary liver malignancy 2. hematologic diseases 3. bud-chiah syndrome 4. incomplete data

Keywords: neutrophil extracellular trap formation portal vein thrombosis hypercoagulability
phase iii daclatasvir and sofosbuvir for genotype 3 chronic hcv

Conditions: Hepatitis C

Summary: to study the combination of daclatasvir and sofosbuvir for the treatment of hepatitis c virus (hcv) genotype 3 infection


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com key inclusion criteria: * subjects must be able to understand and agree to comply with the prescribed dosing regimens and procedures, report for regularly scheduled study visits, and reliably communicate with study personnel about adverse events and concomitant medications * subjects chronically infected with hepatitis c virus (hcv) genotype 3 * subjects who are hcv treatment-naive * subjects who are hcv treatment-experienced (previous exposure to non-structural 5a inhibitors is prohibited) * hcv rna ≥10,000 iu/ml at screening key exclusion criteria: * hcv genotypes other than genotype-3 infection; mixed genotype infections are not permitted * liver or any other organ transplant (including hematopoietic stem cell transplants) other than cornea and hair * current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to screening * documented or suspected hepatocellular carcinoma, as evidenced by previously obtained imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this was performed) * evidence of decompensated liver disease including, but not limited to, radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy
structured training on oncology nurses' performance related port a cath device

Conditions: Port a Cath

Summary: evaluate the effect of structured simulation-based training on oncology nurses' performance regarding port a cath device.

all oncology nurses who are expected to deal with port a-cath device will be recruited in the study pre test will introduced first, then simulated based training will be placed related to port a-cath device care after that , post test will be done immediately and 3 months later to measure nurses knowledge and practice level

Eligibility criteria:
inclusion criteria: * oncology nurses who are providing direct care for patients with port a-cath device exclusion criteria: * participants who will not be able to complete the questionnaire

Keywords: simulated training, oncology nurses, port a cath device
the effect of a low glycemic load diet on hormonal markers associated with acne

Conditions: Acne Vulgaris

Summary: this randomized controlled trial will examine changes in some hormonal markers associated with acne among adults with moderate/severe acne randomized to a low glycemic index and glycemic load diet or usual eating plan for two weeks.

the objectives of this randomized controlled trial are to investigate the impact of a low glycemic index/load eating plan on endocrine aspects of acne. specifically, this study will examine changes in blood biochemical markers of acne among adults with acne following a modified carbohydrate (low glycemic index/load) eating plan or their usual eating plan for two weeks. an external sponsor, nutrisystem®, will provide some low glycemic index/load foods to the study participants randomized to the intervention group for two weeks. study outcomes include changes in glucose, insulin, insulin resistance, insulin-like growth factor-1, and insulin-like growth factor binding protein-3 concentrations.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) ≥18.5 or \<30.0 kg/m2 * history of moderate or severe facial acne for at least 6 months * able to read and speak the english language exclusion criteria: * \> 10% weight change within the last 6 months * taking medications known to alter blood glucose or insulin concentrations * medical history of polycystic ovarian syndrome, type 1 diabetes, type 2 diabetes, or pre diabetes * low carbohydrate (\<45% of total energy from carbohydrate), glycemic index, or glycemic load diet * female participants that are pregnant or lactating or were pregnant or lactating within the last year * current use of a pacemaker or other battery operated implant * facial hair that would make it difficult for a health care provider to assess facial acne.

Keywords: diet glycemic index glycemic load acne vulgaris
pilot to examine risk and feasibility of remote management of bp from childhood into early adulthood

Conditions: Chronic Kidney Diseases; Hypertension; Blood Pressure

Summary: hypertension is an increasingly common problem in children, especially among those who are obese or with diabetes and chronic kidney disease. this study is a pilot randomized controlled trial designed to test whether improved blood pressure control can be achieved with the use of remote home blood pressure monitoring in children with uncontrolled blood pressure.

hypertension is an increasingly common problem in children, especially among those who are obese or with diabetes and chronic kidney disease. this study is a pilot randomized controlled trial designed to test whether improved blood pressure control can be achieved with the use of remote home blood pressure monitoring in children with uncontrolled blood pressure. study investigators will randomize 60 children who have elevated bp (defined as receipt of ≥1 anti-hypertensive agent or office sbp ≥90th percentile) to either home bp monitoring with a home sbp target of \< 90th percentile or less than 120 mm hg, which ever is lower (intervention group) versus usual care group in 2:1 ratio. this study aims to (1) compare the safety of bp lowering in intervention versus usual care patients, (2) determine the efficacy of the intervention and provide estimates for the refinement of sample size determination for an eventual full-scale trial, and (3) assess the feasibility and acceptability of the intervention, recruitment rates, and barriers to trial completion.

Eligibility criteria:
inclusion criteria: * must be receiving at least one anti-hypertensive agent or have an office sbp ≥120 mmhg or \>90th percentile for age, sex or height at the time of the screening visit * have a mid-arm circumference between 22-37cm (bp cuff size limitation) * able to provide consent to participate in our study * able to use smartphones, or able to use any phone to call or text our study personnel with home bp readings. if participant does not have a smartphone, they will be allowed to call, text, or e-mail home bp readings on a weekly basis instead. exclusion criteria: we will exclude those who: * are or are planning to become pregnant, due to inability to take multiple classes of anti-hypertensive agents * are marginally housed, due to concerns regarding routine follow-up * are actively participating in a different interventional trial that may affect blood pressure * are unwilling to consent to participate * institutionalized individuals or prisoners * are actively abusing illicit drugs or alcohol * have a history of poor or doubtful compliance (e.g., frequently missed appointments) * have office sbp \>170 mmhg * are already taking ≥5 anti-hypertensive medications (any classes, including diuretics) * have cognitive impairment prohibiting participation in the study
observational study of the effects intravenous bortezomib has on osteoblast (cell that is responsible for bone formation) activity in multiple myeloma patients.

Conditions: Multiple Myeloma

Summary: the purpose of this study is to measure the markers related to bone metabolism before and after the use of bortezomib injection in patients with multiple myeloma and to evaluate the effect bortezomib injection has on bone disease.

among several symptoms in patients with multiple myeloma, the bone disease is one of the most common symptoms that approximately 80 percent of the patients experience. multiple myeloma is different from other tumors in that several osteoclast activating factors (oaf) released from multiple myeloma cells resorb bone and, at the same time, activation of osteoblast is inhibited, leading to unbalance of breakdown and formation of bone. activation of osteoclast and inhibition of osteoblast brings about bone fractures, osteoporosis, hypercalcemia, bone pain and spinal cord compression. those symptoms are directly related to patients' quality of life. therefore, they are the important therapeutic targets for multiple myeloma. various types of bisphosphonate agents are used for the treatment of the bone disease in patients with multiple myeloma. this is a prospective (a study where the participants are identified and then followed forward in time), multi-center, phase 4, observational study (studies that record specific events occurring without any intervention from the researcher) in order to analyze the change in bone metabolism markers (dkk-1, srankl, opg, srankl/opg,balp, oc) before and after the use of bortezomib injection by using an enzyme-linked immunosorbent assay (elisa) in serum. the adverse events will be assessed through the national cancer institute common terminology criteria for adverse events version 3.0 (nci ctcae v3). the patients will receive bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days under usual clinical practice.

Eligibility criteria:
inclusion criteria: * among patients who are newly prescribed bortezomib injection as a secondary agent for the treatment of multiple myeloma, those of whom agree to provide information will be included. exclusion criteria: * patients who are hypersensitive to the study drug or any component of the study drug or with a history of the hypersensitivity * patients with severe hepatic impairment * women who are pregnant

Keywords: osteoblst effect velcade proteasome inhibitor bortezomib multjple myeloma